1. Home
  2. IMUX vs CODA Comparison

IMUX vs CODA Comparison

Compare IMUX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

SELL

Current Price

$7.91

Market Cap

100.2M

Sector

Health Care

ML Signal

SELL

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$9.01

Market Cap

101.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
CODA
Founded
2016
1994
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
100.2M
101.3M
IPO Year
2013
2007

Fundamental Metrics

Financial Performance
Metric
IMUX
CODA
Price
$7.91
$9.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
2
Target Price
★ $43.09
$14.00
AVG Volume (30 Days)
★ 330.0K
77.9K
Earning Date
11-16-2026
09-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.00
15.62
EPS
N/A
★ 0.36
Revenue
N/A
★ $20,316,161.00
Revenue This Year
N/A
$9.92
Revenue Next Year
N/A
$17.26
P/E Ratio
★ N/A
$25.78
Revenue Growth
N/A
★ 4.98
52 Week Low
$0.51
$7.80
52 Week High
$17.43
$18.00

Technical Indicators

Market Signals
Indicator
IMUX
CODA
Relative Strength Index (RSI) 42.34 39.46
Support Level $6.35 $9.04
Resistance Level $8.60 $10.66
Average True Range (ATR) 0.57 0.37
MACD 0.22 -0.04
Stochastic Oscillator 61.97 28.57

Price Performance

Historical Comparison
IMUX
CODA

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

Share on Social Networks: